<?xml version="1.0" encoding="UTF-8"?>
<p>The diagnosis and follow up of patients with HCV has been simplified by pan-genotypic drug regimens which no longer require genotyping and laboratory follow up testing, and the validation of low-cost approaches to the assessment of liver status (ie, APRI score). Furthermore, clinical trials have shown that treatment can be delivered effectively by trained nurses in community settings [
 <xref rid="R7" ref-type="bibr">7</xref>] and shortened treatment durations, down to 8 weeks for most patients, mean more patients can be treated within the same service capacity.
</p>
